Global Mesalamine (Lialda) 麻豆原创 Research Report 2023

Publication ID:

PB504244255

Publication Date:

May 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease听2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.
Highlights
The global Mesalamine (Lialda) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Mesalamine (Lialda) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Mesalamine (Lialda) in Colitis is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Mesalamine (Lialda) include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria and Lupin, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Mesalamine (Lialda), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine (Lialda).
The Mesalamine (Lialda) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Mesalamine (Lialda) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mesalamine (Lialda) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical
HENGCHENG PHARMACEUTICAL
KWAI FA Pharmaceutical Group
Segment by Type
Enemas
Tablets
Suppositories
Other
Segment by Application
Colitis
Crohn's Disease
Proctitis
Diarrheal Irritable Bowel Syndrome
Diverticulitis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine (Lialda) companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Mesalamine (Lialda) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Enemas
1.2.3 Tablets
1.2.4 Suppositories
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Mesalamine (Lialda) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Colitis
1.3.3 Crohn's Disease
1.3.4 Proctitis
1.3.5 Diarrheal Irritable Bowel Syndrome
1.3.6 Diverticulitis
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Mesalamine (Lialda) 麻豆原创 Perspective (2018-2029)
2.2 Mesalamine (Lialda) Growth Trends by Region
2.2.1 Global Mesalamine (Lialda) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Mesalamine (Lialda) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Mesalamine (Lialda) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Mesalamine (Lialda) 麻豆原创 Dynamics
2.3.1 Mesalamine (Lialda) Industry Trends
2.3.2 Mesalamine (Lialda) 麻豆原创 Drivers
2.3.3 Mesalamine (Lialda) 麻豆原创 Challenges
2.3.4 Mesalamine (Lialda) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Mesalamine (Lialda) Players by Revenue
3.1.1 Global Top Mesalamine (Lialda) Players by Revenue (2018-2023)
3.1.2 Global Mesalamine (Lialda) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Mesalamine (Lialda) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Mesalamine (Lialda) Revenue
3.4 Global Mesalamine (Lialda) 麻豆原创 Concentration Ratio
3.4.1 Global Mesalamine (Lialda) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mesalamine (Lialda) Revenue in 2022
3.5 Mesalamine (Lialda) Key Players Head office and Area Served
3.6 Key Players Mesalamine (Lialda) Product Solution and Service
3.7 Date of Enter into Mesalamine (Lialda) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Mesalamine (Lialda) Breakdown Data by Type
4.1 Global Mesalamine (Lialda) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Mesalamine (Lialda) Forecasted 麻豆原创 Size by Type (2024-2029)
5 Mesalamine (Lialda) Breakdown Data by Application
5.1 Global Mesalamine (Lialda) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Mesalamine (Lialda) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Mesalamine (Lialda) 麻豆原创 Size (2018-2029)
6.2 North America Mesalamine (Lialda) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Mesalamine (Lialda) 麻豆原创 Size by Country (2018-2023)
6.4 North America Mesalamine (Lialda) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Mesalamine (Lialda) 麻豆原创 Size (2018-2029)
7.2 Europe Mesalamine (Lialda) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Mesalamine (Lialda) 麻豆原创 Size by Country (2018-2023)
7.4 Europe Mesalamine (Lialda) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Mesalamine (Lialda) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Mesalamine (Lialda) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Mesalamine (Lialda) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Mesalamine (Lialda) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Mesalamine (Lialda) 麻豆原创 Size (2018-2029)
9.2 Latin America Mesalamine (Lialda) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Mesalamine (Lialda) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Mesalamine (Lialda) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Mesalamine (Lialda) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Mesalamine (Lialda) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Mesalamine (Lialda) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Mesalamine (Lialda) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dr.Falk Pharma
11.1.1 Dr.Falk Pharma Company Detail
11.1.2 Dr.Falk Pharma Business Overview
11.1.3 Dr.Falk Pharma Mesalamine (Lialda) Introduction
11.1.4 Dr.Falk Pharma Revenue in Mesalamine (Lialda) Business (2018-2023)
11.1.5 Dr.Falk Pharma Recent Development
11.2 Ferring
11.2.1 Ferring Company Detail
11.2.2 Ferring Business Overview
11.2.3 Ferring Mesalamine (Lialda) Introduction
11.2.4 Ferring Revenue in Mesalamine (Lialda) Business (2018-2023)
11.2.5 Ferring Recent Development
11.3 Ethypharm Pharmaceutical
11.3.1 Ethypharm Pharmaceutical Company Detail
11.3.2 Ethypharm Pharmaceutical Business Overview
11.3.3 Ethypharm Pharmaceutical Mesalamine (Lialda) Introduction
11.3.4 Ethypharm Pharmaceutical Revenue in Mesalamine (Lialda) Business (2018-2023)
11.3.5 Ethypharm Pharmaceutical Recent Development
11.4 Shanghai Pharmaceutical
11.4.1 Shanghai Pharmaceutical Company Detail
11.4.2 Shanghai Pharmaceutical Business Overview
11.4.3 Shanghai Pharmaceutical Mesalamine (Lialda) Introduction
11.4.4 Shanghai Pharmaceutical Revenue in Mesalamine (Lialda) Business (2018-2023)
11.4.5 Shanghai Pharmaceutical Recent Development
11.5 Tillotts Pharma
11.5.1 Tillotts Pharma Company Detail
11.5.2 Tillotts Pharma Business Overview
11.5.3 Tillotts Pharma Mesalamine (Lialda) Introduction
11.5.4 Tillotts Pharma Revenue in Mesalamine (Lialda) Business (2018-2023)
11.5.5 Tillotts Pharma Recent Development
11.6 Holy Stone Healthcare
11.6.1 Holy Stone Healthcare Company Detail
11.6.2 Holy Stone Healthcare Business Overview
11.6.3 Holy Stone Healthcare Mesalamine (Lialda) Introduction
11.6.4 Holy Stone Healthcare Revenue in Mesalamine (Lialda) Business (2018-2023)
11.6.5 Holy Stone Healthcare Recent Development
11.7 Giuliani
11.7.1 Giuliani Company Detail
11.7.2 Giuliani Business Overview
11.7.3 Giuliani Mesalamine (Lialda) Introduction
11.7.4 Giuliani Revenue in Mesalamine (Lialda) Business (2018-2023)
11.7.5 Giuliani Recent Development
11.8 Zeria
11.8.1 Zeria Company Detail
11.8.2 Zeria Business Overview
11.8.3 Zeria Mesalamine (Lialda) Introduction
11.8.4 Zeria Revenue in Mesalamine (Lialda) Business (2018-2023)
11.8.5 Zeria Recent Development
11.9 Lupin
11.9.1 Lupin Company Detail
11.9.2 Lupin Business Overview
11.9.3 Lupin Mesalamine (Lialda) Introduction
11.9.4 Lupin Revenue in Mesalamine (Lialda) Business (2018-2023)
11.9.5 Lupin Recent Development
11.10 Heilongjiang Tianhong Pharmaceutical
11.10.1 Heilongjiang Tianhong Pharmaceutical Company Detail
11.10.2 Heilongjiang Tianhong Pharmaceutical Business Overview
11.10.3 Heilongjiang Tianhong Pharmaceutical Mesalamine (Lialda) Introduction
11.10.4 Heilongjiang Tianhong Pharmaceutical Revenue in Mesalamine (Lialda) Business (2018-2023)
11.10.5 Heilongjiang Tianhong Pharmaceutical Recent Development
11.11 HENGCHENG PHARMACEUTICAL
11.11.1 HENGCHENG PHARMACEUTICAL Company Detail
11.11.2 HENGCHENG PHARMACEUTICAL Business Overview
11.11.3 HENGCHENG PHARMACEUTICAL Mesalamine (Lialda) Introduction
11.11.4 HENGCHENG PHARMACEUTICAL Revenue in Mesalamine (Lialda) Business (2018-2023)
11.11.5 HENGCHENG PHARMACEUTICAL Recent Development
11.12 KWAI FA Pharmaceutical Group
11.12.1 KWAI FA Pharmaceutical Group Company Detail
11.12.2 KWAI FA Pharmaceutical Group Business Overview
11.12.3 KWAI FA Pharmaceutical Group Mesalamine (Lialda) Introduction
11.12.4 KWAI FA Pharmaceutical Group Revenue in Mesalamine (Lialda) Business (2018-2023)
11.12.5 KWAI FA Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical
HENGCHENG PHARMACEUTICAL
KWAI FA Pharmaceutical Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.